The effect of TNFa-blockers on B-cells in patients with granulomatous diseases.

Completed

• Conditions: Inflammatory systemic diseases; 10017969; 10003816

• Registration Number: NL-OMON41509
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Age > 18 years
Biopsy proven sytemic granulomatous disease as Crohn's Disease/Sarcoidosis
Intention to start treatment with TNFa-blockers; infliximab

Exclusion Criteria

Age < 18

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To assess the B-cell maturation in patients with granulomatous diseases.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>